Prompt clinical response to secukinumab in patients with axial spondyloarthritis: Real life observational data from three italian referral centers

Stefano Gentileschi, Antonio Vitale, Donato Rigante, Giuseppe Lopalco, Giacomo Emmi, Ida Orlando, Gerardo Di Scala, Jurgen Sota, Claudia Fabiani, Bruno Frediani, Mauro Galeazzi, Giovanni Lapadula, Florenzo Iannone, Luca Cantarini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Clinical research is needed to identify patients with axial spondyloarthritis (axSpA) who are more likely to be responsive to interleukin (IL)-17 inhibition. Objectives: To evaluate short-term efficacy of secukinumab in the management of axSpA. Method: Twenty-one patients (7 males, 14 females) with axSpA were consecutively treated with secukinumab. Laboratory and clinical assessments were based on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at a 3 month follow-up visit. Results: The study was comprised of 21 patients. Both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3 month visit (P < 0.0001 and P = 0.0005, respectively). During the laboratory assessment, ESR showed a significant decrease (P = 0.008) while CRP improvement did not reach statistical significance (P = 0.213). No statistical significance was observed between patients treated with secukinumab 150 mg vs. 300 mg in BASDAI (P = 0.99), ASDAS-CRP (P = 0.69), ESR (P = 0.54), and CRP (P = 0.56). No significant differences emerged between the BASDAI (P = 0.15), ASDAS-CRP (P = 0.09), and CRP (P = 0.15) rates in biologic-naïve patients and those previously failing tumor necrosis factor-α inhibition. Conversely, ESR decrease was significantly higher in the biologic-naïve subgroup (P = 0.01). No adverse events were reported. Conclusions: Secukinumab has proven remarkable short-term effectiveness, regardless of the biologic treatment line. A dosage of 150 mg proved to be appropriate in the clinical and laboratory management of axSpA.

Original languageEnglish
Pages (from-to)438-441
Number of pages4
JournalIsrael Medical Association Journal
Volume20
Issue number7
Publication statusPublished - Jul 1 2018

Fingerprint

Ankylosing Spondylitis
C-Reactive Protein
Referral and Consultation
Blood Sedimentation
Baths
Biological Products
Interleukin-17
secukinumab
Tumor Necrosis Factor-alpha
Research

Keywords

  • Axial spondyloarthritis (axSpA)
  • Interleukin (IL)-17
  • Secukinumab
  • Seronegative arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prompt clinical response to secukinumab in patients with axial spondyloarthritis : Real life observational data from three italian referral centers. / Gentileschi, Stefano; Vitale, Antonio; Rigante, Donato; Lopalco, Giuseppe; Emmi, Giacomo; Orlando, Ida; Di Scala, Gerardo; Sota, Jurgen; Fabiani, Claudia; Frediani, Bruno; Galeazzi, Mauro; Lapadula, Giovanni; Iannone, Florenzo; Cantarini, Luca.

In: Israel Medical Association Journal, Vol. 20, No. 7, 01.07.2018, p. 438-441.

Research output: Contribution to journalArticle

Gentileschi, S, Vitale, A, Rigante, D, Lopalco, G, Emmi, G, Orlando, I, Di Scala, G, Sota, J, Fabiani, C, Frediani, B, Galeazzi, M, Lapadula, G, Iannone, F & Cantarini, L 2018, 'Prompt clinical response to secukinumab in patients with axial spondyloarthritis: Real life observational data from three italian referral centers', Israel Medical Association Journal, vol. 20, no. 7, pp. 438-441.
Gentileschi, Stefano ; Vitale, Antonio ; Rigante, Donato ; Lopalco, Giuseppe ; Emmi, Giacomo ; Orlando, Ida ; Di Scala, Gerardo ; Sota, Jurgen ; Fabiani, Claudia ; Frediani, Bruno ; Galeazzi, Mauro ; Lapadula, Giovanni ; Iannone, Florenzo ; Cantarini, Luca. / Prompt clinical response to secukinumab in patients with axial spondyloarthritis : Real life observational data from three italian referral centers. In: Israel Medical Association Journal. 2018 ; Vol. 20, No. 7. pp. 438-441.
@article{2235881197c5474989da9e08f1a36803,
title = "Prompt clinical response to secukinumab in patients with axial spondyloarthritis: Real life observational data from three italian referral centers",
abstract = "Background: Clinical research is needed to identify patients with axial spondyloarthritis (axSpA) who are more likely to be responsive to interleukin (IL)-17 inhibition. Objectives: To evaluate short-term efficacy of secukinumab in the management of axSpA. Method: Twenty-one patients (7 males, 14 females) with axSpA were consecutively treated with secukinumab. Laboratory and clinical assessments were based on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at a 3 month follow-up visit. Results: The study was comprised of 21 patients. Both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3 month visit (P < 0.0001 and P = 0.0005, respectively). During the laboratory assessment, ESR showed a significant decrease (P = 0.008) while CRP improvement did not reach statistical significance (P = 0.213). No statistical significance was observed between patients treated with secukinumab 150 mg vs. 300 mg in BASDAI (P = 0.99), ASDAS-CRP (P = 0.69), ESR (P = 0.54), and CRP (P = 0.56). No significant differences emerged between the BASDAI (P = 0.15), ASDAS-CRP (P = 0.09), and CRP (P = 0.15) rates in biologic-na{\"i}ve patients and those previously failing tumor necrosis factor-α inhibition. Conversely, ESR decrease was significantly higher in the biologic-na{\"i}ve subgroup (P = 0.01). No adverse events were reported. Conclusions: Secukinumab has proven remarkable short-term effectiveness, regardless of the biologic treatment line. A dosage of 150 mg proved to be appropriate in the clinical and laboratory management of axSpA.",
keywords = "Axial spondyloarthritis (axSpA), Interleukin (IL)-17, Secukinumab, Seronegative arthritis",
author = "Stefano Gentileschi and Antonio Vitale and Donato Rigante and Giuseppe Lopalco and Giacomo Emmi and Ida Orlando and {Di Scala}, Gerardo and Jurgen Sota and Claudia Fabiani and Bruno Frediani and Mauro Galeazzi and Giovanni Lapadula and Florenzo Iannone and Luca Cantarini",
year = "2018",
month = "7",
day = "1",
language = "English",
volume = "20",
pages = "438--441",
journal = "Israel Medical Association Journal",
issn = "1565-1088",
publisher = "Israel Medical Association",
number = "7",

}

TY - JOUR

T1 - Prompt clinical response to secukinumab in patients with axial spondyloarthritis

T2 - Real life observational data from three italian referral centers

AU - Gentileschi, Stefano

AU - Vitale, Antonio

AU - Rigante, Donato

AU - Lopalco, Giuseppe

AU - Emmi, Giacomo

AU - Orlando, Ida

AU - Di Scala, Gerardo

AU - Sota, Jurgen

AU - Fabiani, Claudia

AU - Frediani, Bruno

AU - Galeazzi, Mauro

AU - Lapadula, Giovanni

AU - Iannone, Florenzo

AU - Cantarini, Luca

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background: Clinical research is needed to identify patients with axial spondyloarthritis (axSpA) who are more likely to be responsive to interleukin (IL)-17 inhibition. Objectives: To evaluate short-term efficacy of secukinumab in the management of axSpA. Method: Twenty-one patients (7 males, 14 females) with axSpA were consecutively treated with secukinumab. Laboratory and clinical assessments were based on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at a 3 month follow-up visit. Results: The study was comprised of 21 patients. Both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3 month visit (P < 0.0001 and P = 0.0005, respectively). During the laboratory assessment, ESR showed a significant decrease (P = 0.008) while CRP improvement did not reach statistical significance (P = 0.213). No statistical significance was observed between patients treated with secukinumab 150 mg vs. 300 mg in BASDAI (P = 0.99), ASDAS-CRP (P = 0.69), ESR (P = 0.54), and CRP (P = 0.56). No significant differences emerged between the BASDAI (P = 0.15), ASDAS-CRP (P = 0.09), and CRP (P = 0.15) rates in biologic-naïve patients and those previously failing tumor necrosis factor-α inhibition. Conversely, ESR decrease was significantly higher in the biologic-naïve subgroup (P = 0.01). No adverse events were reported. Conclusions: Secukinumab has proven remarkable short-term effectiveness, regardless of the biologic treatment line. A dosage of 150 mg proved to be appropriate in the clinical and laboratory management of axSpA.

AB - Background: Clinical research is needed to identify patients with axial spondyloarthritis (axSpA) who are more likely to be responsive to interleukin (IL)-17 inhibition. Objectives: To evaluate short-term efficacy of secukinumab in the management of axSpA. Method: Twenty-one patients (7 males, 14 females) with axSpA were consecutively treated with secukinumab. Laboratory and clinical assessments were based on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at a 3 month follow-up visit. Results: The study was comprised of 21 patients. Both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3 month visit (P < 0.0001 and P = 0.0005, respectively). During the laboratory assessment, ESR showed a significant decrease (P = 0.008) while CRP improvement did not reach statistical significance (P = 0.213). No statistical significance was observed between patients treated with secukinumab 150 mg vs. 300 mg in BASDAI (P = 0.99), ASDAS-CRP (P = 0.69), ESR (P = 0.54), and CRP (P = 0.56). No significant differences emerged between the BASDAI (P = 0.15), ASDAS-CRP (P = 0.09), and CRP (P = 0.15) rates in biologic-naïve patients and those previously failing tumor necrosis factor-α inhibition. Conversely, ESR decrease was significantly higher in the biologic-naïve subgroup (P = 0.01). No adverse events were reported. Conclusions: Secukinumab has proven remarkable short-term effectiveness, regardless of the biologic treatment line. A dosage of 150 mg proved to be appropriate in the clinical and laboratory management of axSpA.

KW - Axial spondyloarthritis (axSpA)

KW - Interleukin (IL)-17

KW - Secukinumab

KW - Seronegative arthritis

UR - http://www.scopus.com/inward/record.url?scp=85054082105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054082105&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85054082105

VL - 20

SP - 438

EP - 441

JO - Israel Medical Association Journal

JF - Israel Medical Association Journal

SN - 1565-1088

IS - 7

ER -